Morgan Stanley analyst Terence Flynn raised the firm’s price target on Regeneron (REGN) to $768 from $767 and keeps an Equal Weight rating on the ...
Sanofi (NASDAQ:SNY) is a French pharmaceutical firm that has been at the center of several analysts’ attention lately.
Lilly was granted a voucher for its obesity pill, orforglipron, in November as part of a deal with the Trump ...
Investor's Business Daily on MSN
Stocks to watch: Regeneron Pharmaceuticals sees relative strength rating rise to 82
Regeneron Pharmaceuticals earns the No. 76 rank among its peers in the Medical-Biomed/Biotech industry group. Exact Sciences ...
At this year’s American College of Allergy, Asthma & Immunology Scientific Meeting, Anne K. Ellis, MD, MSc, FACAAI, received ...
The biotechnology sector is characterized by significant price swings, and Regeneron Pharmaceuticals is currently navigating one such period. Although the co ...
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...
A recently approved antibody drug from Regeneron Pharmaceuticals eradicates residual traces of multiple myeloma after initial ...
The 23andMe Research Institute bought the company's assets for $305 million, scotching a proposed sale to Regeneron ...
Regeneron's new antibody drug, Lynozyfic, shows promise in eradicating residual multiple myeloma without the need for bone marrow transplants, according to a small mid-stage trial. The treatment ...
After a series of unfortunate regulatory rejections and manufacturing issues surfaced, Regeneron’s shares dipped to $483 this ...
Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic breast cancer, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback